Common Viral infections in Africa: Surveillance for HAI Resp infections

4th Nov 2014, 5th ICAN/ICAZ conference

Division of Global Disease Detection and Emergency Response

Center for Global Health

Dr. Linus Ndegwa, MPHE, HCS,SHEA AmbInfection Control, Manager

Global Disease Detection-GDD

Centers for Disease Control and Prevention-Kenya

Influenza

Influenza: serious respiratory illness, can be debilitating and cause complications leading to hospitalization and death

Most affected: very young, persons with underlying medical conditions and elderly

2

Global impact of influenza

Globally, seasonal influenza causes 3-5 million cases of severe illness and 300,000-500,000 deaths

Past pandemic influenza associated with millions of deaths

1918: “Spanish Flu” 1957: “Asian Flu” 1968: “Hong Kong Flu”

20-40 million deaths 1-4 million deaths 1-4 million deaths 3

Influenza virus

Influenza A and B viruses are of epidemiological interest in humans

Types B and C limited to humans

Type A viruses are more virulent and affect many species

Antigenic determinants of influenza A and B are: Haemagglutinin (HA) and Neuraminidase (NA) glycoproteins

4

Influenza Virus

Hemagglutinin It is a glycoprotein Receptor that binds host cells

inducing penetration of the virus

Antigenic sites at the outer surface

Antibodies to HA are protective

5

Influenza Virus

Neuraminidase (NA): 9 known

Helps release virions from cells

Antibody to NA can help modify disease severity

6

Influenza Virus

Antigenic drift and shift:

arises from mutations in the antigenic sites reducing biding of neutralizing antibodies

7

Influenza Virus

Antigenic shift (genome re-assortment)

arises when the HA is exchanged in a virus e.g. H1 replaced by H5

8

Influenza virus

Influenza A viruses subtypes:

– 16 HA (H1-H17)

– 9 NA (N1-N9) subtypes

9

Epidemiology of Influenza

Virological Pattern: Northern Hemisphere

10

Epidemiology of Influenza

Virological Pattern: Southern Hemisphere

11

Epidemiology of InfluenzaVirological Pattern: Kenya

12

Burden of seasonal influenza in Kenya

Influenza circulates at least 11 months per year Influenza detected in : 10-12% of respiratory hospitalizations annually, >30% during periods of peak circulation 8.7% of rHAI in 30months surveillance

Highest rates in children < 6 months Influenza-associated hospitalizations in children

<5 years are 3-7 times higher than in the United States, despite less care-seeking

persons with HIV more likely to spread influenza in their homes

Current Epidemic and Pandemic Threats!

Pathogen Date of first report

Laboratory-confirmedcases

Deaths Case Fatality Proportion

Date of last reportedcase

A(H5N1) January, 2004 668 393 58.8% Sep, 2014

A(H7N9) February, 2013

453 175 38.6% Aug, 2014

Middle East Respiratory SyndromeCoronavirus

June, 2012 885 319 36% Oct, 2014

Transmission

Influenza viruses transmitted via air droplets Close contact (up to 3-6 feet) is required for transmission Transmission may also occur through:

– direct skin-to-skin contact – indirect contact with respiratory secretions – Touching contaminated surfaces then touching the eyes,

nose or mouth)

15

Transmission

Incubation period 1-2 days

Individuals may spread influenza virus from up to 2 days before to 5 days after onset of symptoms

Children can spread the virus for 10 days or longer

Immunocompromized persons also tend to shed the virus longer

16

Clinical Presentation

17

Complications of Human Influenza

Pneumonia– primary influenza pneumonia the most severe– secondary bacterial pneumonia being the most common – mixed viral and bacterial pneumonia frequently occurs

Secondary bacterial pneumonia is most commonly caused by :– Streptococcus pneumoniae, – Staphylococcus aureus– Haemophilus influenzae

Chronic cardiac and pulmonary disease predispose Reye’s syndrome in children with Flu B

18

Influenza Prevention and Control

Non pharmacologic– Surveillance – Isolation and quarantine– Social distancing– Respiratory protection– Cough and sneeze etiquette– Hand washing

Pharmacologic– Vaccination– Antiviral drugs

19

Historically no routine

surveillance for HAIs

Kenyan hospitals:

– Patient overcrowding

– Inadequate hand hygiene

We set up surveillance

for respiratory HAI started

Infection Control and Prevention in Kenya

Objectives

To document respiratory HAIs occurring on selected wards in 3 Kenyan hospitals

To identify the viruses causing respiratory HAIs

Surveillance sites Prospective surveillance

Site: 3 selected hospitals

– Kenyatta National hospital: 1800 beds

– Mbagathi District hospital: 200 beds

Apr 1, 2010

Wards

– Medical

– Pediatric

– The ICU

Surveillance Sites

Hospitals

Case Definition: Respiratory HAIs

Inclusion Criteria:

– Patients admitted >3 calendar days• Admit date: Day 1

– New onset fever/hypothermia

• (≥38°C or <35°C)

• No fever/hypothermia in past 3 days

– New onset of cough or sore throat

Written consent

Laboratory tests

Nasopharyngeal/oropharyngeal swabs collected

Samples tested by real time RT-PCR

Samples collected and tested for:

– Influenza A & B

– Adenovirus

– Respiratory syncytial virus (RSV)

– Human metapneumovirus (HMPV)

– Parainfluenza virus 1, 2 and 3. (PIV 1,2,3)

Laboratory tests

Specimens positive for influenza A were subtyped

– Seasonal H1N1

– Pandemic H1N1

– H5N1

– H3N2

Surveilance

Surveillance officers at each site

Review of in-patients records for new onset of signs and symptoms

Approved by:

– Kenya Medical Research institute ERC

– CDC- Atlanta IRB

Results

Sampling for Respiratory HAI

18545 cases of fever or hypothermia

documented

1255 occurred >3days after admission

with no fever in past 3days

379 with respiratory symptoms

concurrent with fever/hypothermia

In 17 instances, patient

refused swabbing or no

consent obtained112 Swabbed

Respiratory HAIs : Demographics

Conclusion

Surveillance showed that rHAI occurred consistently during the 30 months period

Rates are similar to those in other developing nations

Most cases were positive for at least 1 viral pathogen

Infection control should be strengthened

Continued HAI surveillance critical to monitor the burden of HAIs and impact of control measures

Acknowledgements

ICAN president: Prof. Shaheen

ICAN president: prof Val

Founder and president OASIS: Prof SolomKin

Kenyatta National Hospital

Mbagathi District Referral Hospital

New Nyanza Provincial Hospital

Ministry of Health – Kenya

CDC – Kenya

Div. Healthcare Quality Promotion

CDC – Atlanta

The findings and conclusions in this presentation/report are those of the

author and do not necessarily represent the views of the Centers for

Disease Control and Prevention

Are there any questions?

ikf7@cdc.gov

Protect your patients. Protect yourself. Protect your family.

Asante Sana (Thank you)